Even if vaccines are now available in most countries, a more effective COVID-19 treatment is still needed.
Researchers conclude that a licensed mixture of antiviral drugs from the Food and Drug Administration (FDA) will benefit people with infections of SARS-CoV-2.
They also mixed medicines to cure hepatitis C with the remedy, which is successful against Ebola.
The race for successful care continues with the rise of worldwide COVID-19 events.
New York City, NY, Mount Sinai Hospital scientists are of the opinion that the secret to the treatment of COVID-19 may be an already-approved mix of drug products in the United States.
Researchers have merged redeliver with various hepatitis C virus (HCV) treatments that physicians administer to hospitalized COVID-19 patients already. They wanted to find a blend that delays the propagation of viruses.
“This is a positive synergy, which will include a new antiviral to suppress COVID-19 when proven by further testing and clinical trials,” says Dr. Gaetano Montelione, Ph.D., Professor of Rensselaer Polytechnic, Troy, New York.
Context of COVID-19
Since the new coronavirus was declared a pandemic in March 2020 by the World Health Organization (WHO), almost 150 million people have caught the virus and some 3 million people died of it.
Researchers have examined many medications and therapies to assist with the treatment of COVID-19 during the last year.
For example, redeliver may be used in a hospital setting to treat COVID-19. Remdesivir will “tarn particular viral enzymes or attack a slow viral replication in the host,” according to an article Trusted Source.
In people with COVID-19, certain corticosteroids, such as dexamethasone, can reduce inflammation.
The use of hydroxychloroquine to treat COVID-19 was also considered by investigators. Doctors have been using hydroxychloroquine to treat malaria and rheumatoid arthritis, but further study has shown that in persons with COVID-19 it has been more harmful than healthy.